Morphine upregulates functional expression of neurokinin-1 receptor in neurons

Journal of Neuroscience Research

Volumn 84, Issue 7, 2006, Pages 1588-1596

  Wan, Qi ^a   Douglas, Steven D ^a   Wang, Xu ^a   Kolson, Dennis L ^b   O'Donnell, Lauren A ^b   Ho, Wen Zhe ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Morphine; Mu opioid receptor; Neurokinin 1; Neurons

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 NITROPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CALCIUM; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLARGINYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; DIAMORPHINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MORPHINE; MU OPIATE RECEPTOR; NALTREXONE; NEUROKININ 1 RECEPTOR; OPIATE ANTAGONIST; OPIATE RECEPTOR; SUBSTANCE P;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; EMBRYO; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; METABOLITE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; UPREGULATION; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CALCIUM; CEREBRAL CORTEX; DRUG INTERACTIONS; EMBRYO; ENZYME ACTIVATION; ENZYME INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; MORPHINE; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; NEURONS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROKININ-1; RECEPTORS, OPIOID, MU; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION;

EID: 33750578843     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21053     Document Type: Article

References (47)

1. Aguiar MS, Brandao ML. 1996. Effects of microinjections of the neuropeptide substance P in the dorsal periaqueductal gray on the behavior of rats in the plus-maze test. Physiol Behav 60:1183-1186.
2. Aicher SA, Punnoose A, Goldberg A. 2000. mu-Opioid receptors often colocalize with the substance P receptor (NK1) in the trigeminal dorsal horn. J Neurosci 20:4345-4354.
3. Bandari PS, Qian J, Yehia G, Seegopaul HP, Harrison JS, Gascon P, Fernandes H, Rameshwar P. 2002. Differences in the expression of neurokinin receptor in neural and bone marrow mesenchymal cells: implications for neuronal expansion from bone marrow cells. Neuropeptides 36:13-21.
4. Baumhaker Y, Gafhi M, Keren O, Sarne Y. 1993. Selective and interactive down-regulation of mu- and delta-opioid receptors in human neuroblastoma SK-N-SH cells. Mol Pharmacol 44:461-467.
5. Bergstrom L, Sakurada T, Terenius L. 1984. Substance P levels in various regions of the rat central nervous system after acute and chronic morphine treatment. Life Sci 35:2375-2382.
6. Chakrabarti S, Yang W, Law PY, Loh HH. 1997. The mu-opioid receptor down-regulates differently from the delta-opioid receptor: requirement of a high affinity receptor/G protein complex formation. Mol Pharmacol 52:105-113.
7. Ding YQ, Nomura S, Kaneko T, Mizuno N. 1995. Co-localization of mu-opioid receptor-like and substance P-like immunoreactivities in axon terminals within the superficial layers of the medullary and spinal dorsal horns of the rat. Neurosci Lett 198:45-48.
8. Drevets WC. 2001. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 11:240-249.
9. Fong TM, Anderson SA, Yu H, Huang RR, Strader CD. 1992. Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor. Mol Pharmacol 41:24-30.
10. Gadd CA, Murtra P, De Felipe C, Hunt SP. 2003. Neurokinin-1 receptor-expressing neurons in the amygdala modulate morphine reward and anxiety behaviors in the mouse. J Neurosci 23:8271-8280.
11. Gallacher DV, Hanley MR, Petersen OH, Roberts ML, Squire-Pollard LG, Yule DI. 1990. Substance P and bombesin elevate cytosolic Ca2+ by different molecular mechanisms in a rat pancreatic acinar cell line. J Physiol 426:193-207.
12. Gavioli EC, Canteras NS, De Lima TC. 1999. Anxiogenic-like effect induced by substance P injected into the lateral septal nucleus. Neuroreport 10:3399-3403.
13. Gavioli EC, Canteras NS, De Lima TC. 2002. The role of lateral septal NK1 receptors in mediating anxiogenic effects induced by intracerebroventricular injection of substance P. Behav Brain Res 134:411-415.
14. Guo CJ, Douglas SD, Gao Z, Wolf BA, Grinspan J, Lai JP, Riedel E, Ho WZ. 2004. Interleukin-1beta upregulates functional expression of neurokinin-1 receptor (NK-1R) via NF-kappaB in astrocytes. Glia 48:259-266.
15. Harrison S, Geppetti P. 2001. Substance p. Int J Biochem Cell Biol 33:555-576.
16. Horner KA, Zadina JE. 2004. Internalization and down-regulation of mu opioid receptors by endomorphins and morphine in SH-SY5Y human neuroblastoma cells. Brain Res 1028:121-132.
17. Khawaja AM, Rogers DF. 1996. Tachykinins: receptor to effector. Int J Biochem Cell Biol 28:721-738.
18. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, Hale JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Carlson EJ, Hargreaves RJ, Rupniak NM. 1998. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281:1640-1645.
19. Krumins SA, Kim DC, Seybold VS, Larson AA. 1989. Modulation of [3H]DAGO binding by substance P (SP) and SP fragments in the mouse brain and spinal cord via MU1 interactions. Neuropeptides 13:225-233.
20. Lai JP, Ho WZ, Kilpatrick LE, Wang X, Tuluc F, Korchak HM, Douglas SD. 2006. Full-length and truncated neurokinin-1 receptor expression and function during monocyte/macrophage differentiation. Proc Natl Acad Sci U S A 103:7771-7776.
21. Lu Y, Zheng HX, Ding YQ, Gong LW, Qin BZ, LiJS. 1997. Coexistence of mu-opioid receptor-like and substance P-like immunoreactivities in the cat dorsal root ganglionic neurons. J Himforsch 38:243-246.
22. Ma W, Zheng WH, Powell K, Jhamandas K, Quirion R. 2001. Chronic morphine exposure increases the phosphorylation of MAP kinases and the transcription factor CREB in dorsal root ganglion neurons: an in vitro and in vivo study. Eur J Neurosci 14:1091-1104.
23. Mahajan SD, Schwartz SA, Aalinkeel R, Chawda RP, Sykes DE, Nair MP. 2005. Morphine modulates chemokine gene regulation in normal human astrocytes. Clin Immunol 115:323-332.
24. Maldonado R, Girdlestone D, Roques BP. 1993. RP 67580, a selective antagonist of neurokinin-1 receptors, modifies some of the naloxone-precipitated morphine withdrawal signs in rats. Neurosci Lett 156:135-140.
25. Mantyh PW. 2002. Neurobiology of substance P and the NK1 receptor. J Clin Psychiatry 63(Suppl):6-10.
26. McCarson KE, Krause JE. 1995. The formalin-induced expression of tachykinin peptide and neurokinin receptor messenger RNAs in rat sensory ganglia and spinal cord is modulated by opiate pre administration. Neuroscience 64:729-739.
27. Minami M, Maekawa K, Yabuuchi K, Satoh M. 1995. Double in situ hybridization study on coexistence of mu-, delta- and kappa-opioid receptor mRNAs with pre-protachykinin A mRNA in the rat dorsal root ganglia. Brain Res Mol Brain Res 30:203-210.
28. Morley JE, Yamada T, Walsh JH, Lamers CB, Wong H, Shulkes A, Damassa DA, Gordon J, Carlson HE, Hershman JM. 1980. Morphine addiction and withdrawal alters brain peptide concentrations. Life Sci 26:2239-2244.
29. Murtra P, Sheasby AM, Hunt SP, De Felipe C. 2000. Rewarding effects of opiates are absent in mice lacking the receptor for substance P. Nature 405:180-183.
30. Nikolaus S, Huston JP, Hasenohrl RU. 1999. The neurokinin-1 receptor antagonist WIN51,708 attenuates the anxiolytic-like effects of ventral pallidal substance P injection. Neuroreport 10:2293-2296.
31. Nunes E, Quitkin F, Brady R, Post-Koenig T. 1994. Antidepressant treatment in methadone maintenance patients. J Addict Dis 13:13-24.
32. Nunes EV, Sullivan MA, Levin FR. 2004. Treatment of depression in patients with opiate dependence. Biol Psychiatry 56:793-802.
33. O'Donnell LA, Agrawal A, Jordan-Sciutto KL, Dichter MA, Lynch DR, Kolson DL. 2006. Human immunodeficiency virus (HIV)-induced neurotoxicity: roles for the NMDA receptor subtypes. J Neurosci 26:981-990.
34. Polakiewicz RD, Schieferl SM, Dorner LF, Kansra V, Comb MJ. 1998a. A mitogen-activated protein kinase pathway is required for mu-opioid receptor desensitization. J Biol Chem 273:12402-12406.
35. Polakiewicz RD, Schieferl SM, Gingras AC, Sonenberg N, Comb MJ. 1998b. mu-Opioid receptor activates signaling pathways implicated in cell survival and translational control. J Biol Chem 273:23534-23541.
36. Ranga K, Krishnan R. 2002. Clinical experience with substance P receptor (NK1) antagonists in depression. J Clin Psychiatry 63(Suppl):25-29.
37. Rupniak NM, Carlson EC, Harrison T, Oates B, Seward E, Owen S, de Felipe C, Hunt S. Wheeldon A. 2000. Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalization in guinea-pigs and mice. Neuropharmacology 39:1413-1421.
38. Rupniak NM, Kramer MS. 1999. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci 20:485-490.
39. Sakamoto N, Takatsuji K, Shiosaka S, Tohyama M. 1985. Evidence for the existence of substance P-like immunoreactive neurons in the human cerebral cortex: an immunohistochemical analysis. Brain Res 325:322-324.
40. Santarelli L, Gobbi G, Debs PC, Sibille ET, Blier P, Hen R, Heath MJ. 2001. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci U S A 98:1912-1917.
41. Schedlowski M, Fluge T, Richter S, Tewes U, Schmidt RE, Wagner TO. 1995. Beta-endorphin, but not substance-P, is increased by acute stress in humans. Psychoneuroendocrinology 20:103-110.
42. Shi X GN, Guo QM, Yang YJ, Huo MD, Hu HL, Fness H. 2003. Relationship between overexpression of NK-1R, NK-2R and intestinal mucosal damage in acute necrotizing pancreatitis. World J Gastroenterol 9:160-164.
43. Teixeira RM, Santos AR, Ribeiro SJ, Calixto JB, Rae GA, De Lima TC. 1996. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur J Pharmacol 311:7-14.
44. Tiong GK, Pierce TL, Olley JE. 1992. Sub-chronic exposure to opiates in the rat: effects on brain levels of substance P and calcitonin gene-related peptide during dependence and withdrawal. J Neurosci Res 32:569-375.
45. Wang X, Douglas SD, Commons KG, Pleasure DE, Lai J, Ho C, Bannerman P, Williams M, Ho W. 2004. A non-peptide substance P antagonist (CP-96,345) inhibits morphine-induced NF-kappa B promoter activation in human NT2-N neurons. J Neurosci Res 75:544-553.
46. Weiss DW, Hirt R, Tarcic N, Berzon Y, Ben-Zur H, Breznitz S, Glaser B, Grover NB, Baras M, O'Dorisio TM. 1996. Studies in psychoneuroimmunology: psychological, immunological, and neuroendocrinological parameters in Israeli civilians during and after a period of Scud missile attacks. Behav Med 22:5-14.
47. Wilcox KS, Buchhalter J, Dichter MA. 1994. Properties of inhibitory and excitatory synapses between hippocampal neurons in very low density-cultures. Synapse 18:128-151.